Exozymes (EXOZ) Competitors $12.81 -0.34 (-2.59%) As of 06/13/2025 11:09 AM Eastern Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsSEC FilingsTrendsBuy This Stock EXOZ vs. MREO, BNTC, ERAS, TECX, RAPP, SAGE, ETON, KMDA, ORGO, and ITOSShould you be buying Exozymes stock or one of its competitors? The main competitors of Exozymes include Mereo BioPharma Group (MREO), Benitec Biopharma (BNTC), Erasca (ERAS), Tectonic Therapeutic (TECX), Rapport Therapeutics (RAPP), Sage Therapeutics (SAGE), Eton Pharmaceuticals (ETON), Kamada (KMDA), Organogenesis (ORGO), and iTeos Therapeutics (ITOS). These companies are all part of the "pharmaceutical products" industry. Exozymes vs. Its Competitors Mereo BioPharma Group Benitec Biopharma Erasca Tectonic Therapeutic Rapport Therapeutics Sage Therapeutics Eton Pharmaceuticals Kamada Organogenesis iTeos Therapeutics Mereo BioPharma Group (NASDAQ:MREO) and Exozymes (NASDAQ:EXOZ) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their valuation, institutional ownership, analyst recommendations, profitability, dividends, risk, media sentiment, earnings and community ranking. Do analysts prefer MREO or EXOZ? Mereo BioPharma Group presently has a consensus target price of $7.67, indicating a potential upside of 177.78%. Given Mereo BioPharma Group's stronger consensus rating and higher probable upside, equities analysts clearly believe Mereo BioPharma Group is more favorable than Exozymes.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Mereo BioPharma Group 0 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 1 Strong Buy rating(s) 3.17Exozymes 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Does the media favor MREO or EXOZ? In the previous week, Mereo BioPharma Group had 4 more articles in the media than Exozymes. MarketBeat recorded 6 mentions for Mereo BioPharma Group and 2 mentions for Exozymes. Mereo BioPharma Group's average media sentiment score of 1.04 beat Exozymes' score of 0.94 indicating that Mereo BioPharma Group is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Mereo BioPharma Group 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Exozymes 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Which has better earnings & valuation, MREO or EXOZ? Exozymes has lower revenue, but higher earnings than Mereo BioPharma Group. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioMereo BioPharma Group$1M438.84-$29.47M-$0.07-39.43ExozymesN/AN/AN/AN/AN/A Do insiders & institutionals have more ownership in MREO or EXOZ? 62.8% of Mereo BioPharma Group shares are owned by institutional investors. 5.5% of Mereo BioPharma Group shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth. Is MREO or EXOZ more profitable? Company Net Margins Return on Equity Return on Assets Mereo BioPharma GroupN/A N/A N/A Exozymes N/A N/A N/A Does the MarketBeat Community prefer MREO or EXOZ? Mereo BioPharma Group received 54 more outperform votes than Exozymes when rated by MarketBeat users. CompanyUnderperformOutperformMereo BioPharma GroupOutperform Votes5480.60% Underperform Votes1319.40%ExozymesN/AN/A SummaryMereo BioPharma Group beats Exozymes on 10 of the 10 factors compared between the two stocks. Get Exozymes News Delivered to You Automatically Sign up to receive the latest news and ratings for EXOZ and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding EXOZ and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart EXOZ vs. The Competition Export to ExcelMetricExozymesBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$107.19M$3.09B$5.57B$8.51BDividend YieldN/A1.56%5.27%4.16%P/E RatioN/A32.6326.7519.65Price / SalesN/A455.18404.17152.18Price / CashN/A168.6838.2534.64Price / BookN/A3.366.964.59Net IncomeN/A-$72.35M$3.23B$248.23M7 Day Performance-4.69%0.36%-1.22%-1.07%1 Month Performance-5.53%16.10%6.34%2.59%1 Year PerformanceN/A-15.37%33.05%13.50% Exozymes Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)EXOZExozymesN/A$12.81-2.6%N/AN/A$107.19MN/A0.0029MREOMereo BioPharma Group1.6925 of 5 stars$2.75+3.8%$7.71+180.5%-35.1%$437.25M$1M-39.2940Positive NewsAnalyst RevisionBNTCBenitec Biopharma2.4862 of 5 stars$16.41-0.9%$24.71+50.6%+125.4%$430.76M$80K-10.8720Positive NewsERASErasca2.6802 of 5 stars$1.51-0.7%$4.57+202.7%-31.8%$427.76MN/A-1.82120Positive NewsTECXTectonic Therapeutic3.287 of 5 stars$22.45-4.5%$82.33+266.7%N/A$419.21MN/A-3.81120Analyst ForecastGap DownRAPPRapport Therapeutics1.9513 of 5 stars$11.40-5.8%$32.67+186.5%N/A$416.08MN/A-3.30N/APositive NewsSAGESage Therapeutics3.5597 of 5 stars$6.57-3.0%$8.87+35.0%-44.2%$411.42M$47.40M-1.00690ETONEton Pharmaceuticals2.2827 of 5 stars$14.95-0.9%$29.67+98.4%+301.7%$400.93M$48.33M-67.9520Short Interest ↑KMDAKamada3.8789 of 5 stars$6.94-0.1%$14.67+111.3%+34.9%$399.09M$167.24M24.79360Positive NewsShort Interest ↑ORGOOrganogenesis4.6051 of 5 stars$3.12-4.0%$5.50+76.3%+23.3%$395.78M$458.76M-52.00950Positive NewsAnalyst RevisionITOSiTeos Therapeutics3.7346 of 5 stars$10.00flat$15.86+58.6%-37.3%$382.74M$35M-3.1790Insider Trade Related Companies and Tools Related Companies Mereo BioPharma Group Competitors Benitec Biopharma Competitors Erasca Competitors Tectonic Therapeutic Competitors Rapport Therapeutics Competitors Sage Therapeutics Competitors Eton Pharmaceuticals Competitors Kamada Competitors Organogenesis Competitors iTeos Therapeutics Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:EXOZ) was last updated on 6/15/2025 by MarketBeat.com Staff From Our PartnersTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredWhy July 22nd Could Mean Big Changes for Social SecurityIn a stunning move, President Trump has authorized an AI-led transformation of federal agencies, including Soc...Altimetry | SponsoredAn AI run of epic proportions is only getting startedI just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredNew Rule Hits in July — The Smart Money Already MovedA little-known regulation quietly goes into effect this July. And it's already being exploited by Wall Stre...American Alternative | SponsoredTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | SponsoredBanks aren’t ready for this altcoin—are you?Donald Trump just fast-tracked TWO major crypto bills with an August deadline! Your window of opportunity i...Crypto 101 Media | SponsoredREVEALED FREE: Our top 3 stocks to own in 2025 and beyondEvery time Weiss Ratings flashed green like this, the average gain on each and every stock has been 303% (incl...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Exozymes Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Exozymes With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy EXOZ Stock Free EXOZ Stock Alerts